Please enable Javascript

Labmeeting uses lots of Javascript - basically you can't use the site without it. So please enable Javascript in your browser. If your browser does not support Javascript, we recommend Firefox.

Papers authored by Markman M

Collect these papers and discover other ones on Labmeeting. Learn more.

"Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma" Safra T, et al (Gynecol Oncol 2009; 114:215-218).

+ cite this

Markman M

Gynecologic oncology 115(3):514; author reply 514-5, 2009 Dec - Who cited this? | PubMed ID: 19766296 | Fulltext

Comparative effectiveness research: A proposal for funding in ovarian cancer.

+ cite this

Markman M

Gynecologic oncology 115(2):182-3, 2009 Nov - Who cited this? | PubMed ID: 19695689 | Fulltext

Phase I clinical trials in 56 patients with thyroid cancer: the m. D. Anderson cancer center experience.

+ cite this

+ View Abstract

Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, and Kurzrock R

The Journal of clinical endocrinology and metabolism 94(11):4423-32, 2009 Nov - Who cited this? | PubMed ID: 19820016 | Fulltext

Ovarian cancer.

+ cite this

+ View Abstract

Hennessy BT, Coleman RL, and Markman M

Lancet 374(9698):1371-82, 2009 Oct 17 - Who cited this? | PubMed ID: 19793610 | Fulltext

Antiangiogenic drugs in ovarian cancer.

+ cite this

+ View Abstract

Markman M

Expert opinion on pharmacotherapy 10(14):2269-77, 2009 Oct - Who cited this? | PubMed ID: 19671017 | Fulltext

Chemotherapy: Topotecan or treosulfan--that is the question.

+ cite this

Markman M

Nature reviews. Clinical oncology 6(10):559-60, 2009 Oct - Who cited this? | PubMed ID: 19786996 | Fulltext

PET/CT scans in ovarian cancer: prognostic versus predictive utility?.

+ cite this

+ View Abstract

Markman M

Minerva medica 100(5):415-20, 2009 Oct - Who cited this? | PubMed ID: 19910893 | Fulltext

The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project.

+ cite this

Markman M

Gynecologic oncology 114(3):536; author reply 536-7, 2009 Sep - Who cited this? | PubMed ID: 19482342 | Fulltext

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m(2)) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.

+ cite this

+ View Abstract

Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, and Alberts D

Gynecologic oncology 114(2):195-8, 2009 Aug - Who cited this? | PubMed ID: 19447479 | Fulltext

Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.

+ cite this

+ View Abstract

Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu PY, and Markman M

Gynecologic oncology 114(2):206-9, 2009 Aug - Who cited this? | PubMed ID: 19464730 | Fulltext

Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study.

+ cite this

+ View Abstract

McMeekin DS, Lisyanskaya A, Crispens M, Oza AM, Braly P, Doering D, Bayever E, Michiels B, and Markman M

Gynecologic oncology 114(2):288-92, 2009 Aug - Who cited this? | PubMed ID: 19476988 | Fulltext

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.

+ cite this

Markman M

Gynecologic oncology 114(1):136-7; authore reply 137, 2009 Jul - Who cited this? | PubMed ID: 19138792 | Fulltext

Presentation of chemotherapy options for cervix cancer on cancer-related Internet sites.

+ cite this

+ View Abstract

Markman M

Journal of women's health (2002) 18(6):827-9, 2009 Jun - Who cited this? | PubMed ID: 19514823 | Fulltext

Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation.

+ cite this

Markman M

Gynecologic oncology 113(1):4-5, 2009 Apr - Who cited this? | PubMed ID: 19176238 | Fulltext

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.

+ cite this

+ View Abstract

Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, and Armstrong DK

Cancer 115(7):1395-403, 2009 Apr 1 - Who cited this? | PubMed ID: 19195045 | Fulltext

Prevalence of pulmonary hypertension in patients with schistosomal liver fibrosis.

+ cite this

+ View Abstract

Ferreira RC, Domingues AL, Bandeira AP, Markman Filho B, Albuqerque Filho ES, Correiade de Araújo AC, Batista LJ, Markman M, and Campelo AR

Annals of tropical medicine and parasitology 103(2):129-43, 2009 Mar - Who cited this? | PubMed ID: 19208297 | Fulltext

Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.

+ cite this

+ View Abstract

Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR, Markman M, and Alberts DS

Gynecologic oncology 112(3):444-9, 2009 Mar - Who cited this? | PubMed ID: 19138791 | Fulltext

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma : a Gynecologic Oncology Group study.

+ cite this

+ View Abstract

Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, and Armstrong DK

Cancer 115(5):1028-35, 2009 Mar 1 - Who cited this? | PubMed ID: 19156927 | Fulltext

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the american society of clinical oncology.

+ cite this

+ View Abstract

Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G,

(show remaining authors)

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(5):812-26, 2009 Feb 10 - Who cited this? | PubMed ID: 19103723 | Fulltext

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.

+ cite this

+ View Abstract

Markman M

Therapeutics and clinical risk management 5(1):161-8, 2009 Feb - Who cited this? | PubMed ID: 19436618 | Fulltext

Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.

+ cite this

Markman M

Current oncology reports 11(1):1-2, 2009 Jan - Who cited this? | PubMed ID: 19080733 | Fulltext

The myth of measurable disease in ovarian cancer: revisited.

+ cite this

+ View Abstract

Markman M

Cancer investigation 27(1):11-2, 2009 Jan - Who cited this? | PubMed ID: 19160094 | Fulltext

Therapeutic intent in the conduct of phase I antineoplastic drug trials.

+ cite this

Markman M

Oncology 76(3):149-50, 2009 - Who cited this? | PubMed ID: 19169045 | Fulltext

Hypersensitivity reactions: an increasingly recognized toxicity of platinum agents.

+ cite this

Markman M

Oncology 76(4):229-30, 2009 - Who cited this? | PubMed ID: 19246946 | Fulltext

An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.

+ cite this

+ View Abstract

Markman M

Cancer journal (Sudbury, Mass.) 15(2):105-9, 2009 - Who cited this? | PubMed ID: 19390303 | Fulltext

Clinical Utility of CA-125 for Maintenance Therapy in the Treatment of Advanced Stage Ovarian Carcinoma.

+ cite this

+ View Abstract

Micha JP, Goldstein BH, Rettenmaier MA, Brown JV, John CR, and Markman M

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 19(2):239-41, 2009 - Who cited this? | PubMed ID: 19396000 | Fulltext

Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.

+ cite this

+ View Abstract

Markman M, Brady M, Hutson A, and Berek JS

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 19(2):223-9, 2009 - Who cited this? | PubMed ID: 19395997 | Fulltext

Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience.

+ cite this

+ View Abstract

Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, and Markman M

Oncology 77(2):75-81, 2009 - Who cited this? | PubMed ID: 19571599 | Fulltext

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

+ cite this

Markman M

Cancer 113(10):2832-3, 2008 Nov 15 - Who cited this? | PubMed ID: 18846540 | Fulltext

Predictive value of neoadjuvant chemotherapy for the clinical utility of subsequently performed major cancer surgery.

+ cite this

Markman M

Current oncology reports 10(6):447-8, 2008 Nov - Who cited this? | PubMed ID: 18928657 | Fulltext

The remarkable "paclitaxel story": How many chapters remain to be written?.

+ cite this

Markman M

Gynecologic oncology 111(1):7-8, 2008 Oct - Who cited this? | PubMed ID: 18682311 | Fulltext

Risk of toxicity versus risk of death: a complex equation in the management of highly curable malignancies.

+ cite this

Markman M

Current oncology reports 10(5):359-60, 2008 Sep - Who cited this? | PubMed ID: 18706261 | Fulltext

Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: A strategy to improve the quality of gynecologic cancer clinical research.

+ cite this

Markman M

Gynecologic oncology 110(3):275-7, 2008 Sep - Who cited this? | PubMed ID: 18586312 | Fulltext

Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.

+ cite this

+ View Abstract

Markman M

Trends in pharmacological sciences, 2008 Aug 28 - Who cited this? | PubMed ID: 18760845 | Fulltext

Society of gynecologic oncologists position paper: breast cancer care.

+ cite this

Orr J, Kelley J, Dizon D, Escobar P, Fleming E, Gemignani M, Hetzel D, Hoskins W, Kieback D, Kilgore L, Lapolla J, Lewin S, Lucci J, Markman M, Pothuri B, Powell CB,

(show remaining authors)

Gynecologic oncology 110(1):7-12, 2008 Jul - Who cited this? | PubMed ID: 18589209 | Fulltext

Diagnostic evaluations of unproven clinical utility in oncology: a real-life example of their harmful consequences.

+ cite this

Markman M

Current oncology reports 10(4):271-2, 2008 Jul - Who cited this? | PubMed ID: 18778550 | Fulltext

Second-line Therapy for Ovarian Cancer.

+ cite this

Markman M

Clinical advances in hematology & oncology : H&O 6(6):421-2, 2008 Jun - Who cited this? | PubMed ID: 18567987 | Fulltext

Assigning a cause for a particular outcome in oncology: a serious note of caution.

+ cite this

Markman M

Cancer, 2008 May 27 - Who cited this? | PubMed ID: 18506763 | Fulltext

An ethical argument in support of interactions between developing world countries and pharmaceutical/biotechnology companies involved in oncology drug development.

+ cite this

Markman M

Cancer 112(9):1871-3, 2008 May 1 - Who cited this? | PubMed ID: 18318430 | Fulltext

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival.

+ cite this

+ View Abstract

Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M, and GRACES Clinical Trial Consortium

Gynecologic oncology 109(2):174-81, 2008 May - Who cited this? | PubMed ID: 18314182 | Fulltext

Benefits of religious beliefs for cancer patients: a response to dawkins and hitchens.

+ cite this

Markman M

Current oncology reports 10(3):185-7, 2008 May - Who cited this? | PubMed ID: 18765147 | Fulltext

Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.

+ cite this

+ View Abstract

Fader AN, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, Belinson J, and Rose P

Gynecologic oncology 109(1):33, 2008 Apr - Who cited this? | PubMed ID: 18261784 | Fulltext

Evidence-based chemotherapy administration in advanced ovarian cancer: An impressive past, a disquieting present and an uncertain future.

+ cite this

Markman M

Gynecologic oncology 109(1):4-7, 2008 Apr - Who cited this? | PubMed ID: 18234303 | Fulltext

Further evidence of clinical benefit associated with participation in phase I oncology trials.

+ cite this

Markman M

British journal of cancer 98(6):1021-2, 2008 Mar 25 - Who cited this? | PubMed ID: 18349816 | Fulltext

"Conflict-of-interest" and participation in IRB deliberations: an alternative perspective.

+ cite this

+ View Abstract

Markman M

Cancer investigation 26(2):115-7, 2008 Mar - Who cited this? | PubMed ID: 18259940 | Fulltext

Critical thinking: An essential role in both the conduct and interpretation of gynecologic cancer clinical research.

+ cite this

Markman M

Gynecologic oncology 108(3):462-5, 2008 Mar - Who cited this? | PubMed ID: 18001822 | Fulltext

Re: "Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials".

+ cite this

Markman M

Gynecologic oncology 108(3):658, 2008 Mar - Who cited this? | PubMed ID: 18201751 | Fulltext

Combination versus sequential chemotherapy administration: is it time for a reevaluation of the issue?.

+ cite this

Markman M

Current oncology reports 10(2):93-4, 2008 Mar - Who cited this? | PubMed ID: 18377820 | Fulltext

Objective data rather than opinion in the interpretation of the legitimate goals of phase 1 oncology trials.

+ cite this

Markman M

Cancer investigation 26(1):11-2, 2008 Feb - Who cited this? | PubMed ID: 18181039 | Fulltext

Taxanes in the management of gynecologic malignancies.

+ cite this

+ View Abstract

Markman M

Expert review of anticancer therapy 8(2):219-26, 2008 Feb - Who cited this? | PubMed ID: 18279063 | Fulltext

Search Google Scholar for Markman M

Join Labmeeting

Organize and search your PDF collection
Collect papers
Search millions of papers
Keep up to date with paper alerts
Read your papers from anywhere
Recommend papers to colleagues
Manage your lab

Labmeeting is a web service for researchers. Sign up with your academic email address.

Individuals or corporations not affiliated with an academic institution can request a trial subscription.

Got a question?
The Labmeeting Network
has the answer.
Ask scientists at top universities like Harvard, Stanford, and MIT for their expert opinion!